Valeant Pharmaceuticals may sell its eye surgery equipment business, according to Dow Jones.
Talks are still in their preliminary stages, but the business could sell for as much as $2.5 billion.
On Tuesday the company announced that it is in talks to sell one of its core businesses, Salix, to Takeda for $10 billion.
The beleaguered company is trying to sell assets to bring down its over $30 billion in debt.
More on this to come…